Short answer
Spero Therapeutics Inc (SPRO) filed an 8-K current report with the SEC on October 27, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). COO Timothy Keutzer retiring December 31, 2026 after 11 years with Spero Therapeutics.
Spero Therapeutics Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- COO Timothy Keutzer retiring December 31, 2026 after 11 years with Spero Therapeutics
- Transition consulting expected through approximately February 28, 2027, terminable on 15 days’ notice
- Hourly consulting compensation during transition, with no rate disclosed
- Leadership succession and operational continuity become near-term investor considerations
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Spero Therapeutics Inc 8-K filings
Get the next SPRO 8-K as it lands
Follow SPRO for push alerts, or ask the research agent what this filing means.